Organisms | Evidence |
---|---|
Human immunodeficiency virus 1 |
Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
---|---|---|---|---|---|---|
C1GALT1 | (not applicable) |
|
Ser/Thr |
|
Ser/Thr | |
ST6GALNAC1 | CMP-Neu5Ac |
|
Ser/Thr |
|
Ser/Thr | |
ST6GALNAC1 | CMP-Neu5Ac |
|
O-glycan Synthesis |
|
O-glycan Synthesis | |
B3GNT6 | UDP-GlcNAc |
|
[alpha]-pNP |
|
[alpha]-pNP |
Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
---|---|---|---|---|---|---|
C1GALT1 | (not applicable) |
|
Ser/Thr |
|
Ser/Thr | |
ST6GALNAC1 | CMP-Neu5Ac |
|
Ser/Thr |
|
Ser/Thr | |
ST6GALNAC4 | CMP-Neu5Ac |
|
benzyl |
|
benzyl | |
ST6GALNAC1 | CMP-Neu5Ac |
|
O-glycan Synthesis |
|
O-glycan Synthesis | |
ST6GALNAC1 | CMP-Neu5Ac |
|
[Ala-Thr(*)-Ala]2-7 |
|
[Ala-Thr(*)-Ala]2-7 |
Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Reference |
---|---|---|---|---|
ST6GALNAC3 | CMP-Neu5Ac |
|
Ser/Thr | |
ST6GAL2 | CMP-Neu5Ac |
|
para-nitrophenol | |
ST6GALNAC2 | CMP-Neu5Ac |
|
benzyl | |
ST6GALNAC1 | CMP-Neu5Ac |
|
[alpha]-Bz | |
ST6GALNAC2 | CMP-Neu5Ac |
|
Ser/Thr |
Pathway Name | Organism |
---|---|
E.coli O101 | Escherichia coli |
E.coli O103 | Escherichia coli |
E.coli O107 | Escherichia coli |
E.coli O112ab | Escherichia coli |
E.coli O112ac | Escherichia coli |
E.coli O116 | Escherichia coli |
E.coli O117 | Escherichia coli |
E.coli O125ab | Escherichia coli |
E.coli O127 | Escherichia coli |
E.coli O128ab-H27 | Escherichia coli |
RES 1b:a-dgal-HEX-1:5 2s:n-acetyl LIN 1:1d(2+1)2n
PubMed ID | Title | First Author | Publication Date | Source |
---|---|---|---|---|
35531651 | Givosiran for the treatment of acute hepatic porphyria | Ricci A | 2022 Apr 03 |
|
34826537 | Structural and mechanistic insights into the substrate specificity and hydrolysis of GH31 α-N-acetylgalactosaminidase | Miyazaki T | 2022 Apr |
|
34510420 | A Drug‐Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver | Vassiliou D | 2021 Sep 28 |
|
34549685 | Inhibition of O-glycosylation aggravates GalN/LPS-induced liver injury through activation of ER stress | Xu D | 2021 Sep 22 |
|
34260280 | Adeno-associated Virus 9 Structural Rearrangements Induced by Endosomal Trafficking pH and Glycan Attachment | Penzes JJ | 2021 Sep 09 |
|
34126457 | N-acetylgalactosamine-decorated nanoliposomes for targeted delivery of paclitaxel to hepatocellular carcinoma | Li T | 2021 Oct 15 |
|
34648028 | Overcoming GNA/RNA base-pairing limitations using isonucleotides improves the pharmacodynamic activity of ESC+ GalNAc-siRNAs | Schlegel MK | 2021 Oct 14 |
|
34616040 | A single sulfatase is required to access colonic mucin by a gut bacterium | Luis AS | 2021 Oct 06 |
|
34091052 | Ligand conjugate SAR and enhanced delivery in NHP | Holland RJ | 2021 Oct 06 |
|
34717041 | Efficacy and safety of givosiran for acute hepatic porphyria: 24‐month interim analysis of the randomized phase 3 ENVISION study | Ventura P | 2021 Nov 16 |
|
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
This work is licensed under Creative Commons Attribution 4.0 International
GlyCosmos Portal v4.2.1
Last updated: April 7, 2025